1
|
Naranbhai V, de Assis Rosa D, Werner L, Moodley R, Hong H, Kharsany A, Mlisana K, Sibeko S, Garrett N, Chopera D, Carr WH, Abdool Karim Q, Hill AVS, Abdool Karim SS, Altfeld M, Gray CM, Ndung'u T. Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women. BMC Infect Dis 2016; 16:27. [PMID: 26809736 PMCID: PMC4727384 DOI: 10.1186/s12879-016-1361-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Accepted: 01/18/2016] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND Killer-cell Immunoglobulin-like Receptors (KIR) interact with Human Leukocyte Antigen (HLA) to modify natural killer- and T-cell function. KIR are implicated in HIV acquisition by small studies that have not been widely replicated. A role for KIR in HIV disease progression is more widely replicated and supported by functional studies. METHODS To assess the role of KIR and KIR ligands in HIV acquisition and disease course, we studied at-risk women in South Africa between 2004-2010. Logistic regression was used for nested case-control analysis of 154 women who acquired vs. 155 who did not acquire HIV, despite high exposure. Linear mixed-effects models were used for cohort analysis of 139 women followed prospectively for a median of 54 months (IQR 31-69) until 2014. RESULTS Neither KIR repertoires nor HLA alleles were associated with HIV acquisition. However, KIR haplotype BB was associated with lower viral loads (-0.44 log10 copies/ml; SE = 0.18; p = 0.03) and higher CD4+ T-cell counts (+80 cells/μl; SE = 42; p = 0.04). This was largely explained by the protective effect of KIR2DL2/KIR2DS2 on the B haplotype and reciprocal detrimental effect of KIR2DL3 on the A haplotype. CONCLUSIONS Although neither KIR nor HLA appear to have a role in HIV acquisition, our data are consistent with involvement of KIR2DL2 in HIV control. Additional studies to replicate these findings are indicated.
Collapse
Affiliation(s)
- V Naranbhai
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. .,Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK. .,HIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, South Africa.
| | - D de Assis Rosa
- National Institute of Communicable Diseases, Sandringham, South Africa. .,University of the Witwatersrand, Johannesburg, South Africa.
| | - L Werner
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
| | - R Moodley
- HIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, South Africa.
| | - H Hong
- Division of Virology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
| | - A Kharsany
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
| | - K Mlisana
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
| | - S Sibeko
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
| | - N Garrett
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
| | - D Chopera
- University of Cape Town, Cape Town, South Africa.
| | - W H Carr
- HIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, South Africa. .,City University of New York - Medgar Evers College, New York, USA. .,Ragon Institute of MGH, MIT and Harvard University, Boston, USA.
| | - Q Abdool Karim
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. .,Mailman School of Public Health, Columbia University, New York, USA.
| | - A V S Hill
- Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
| | - S S Abdool Karim
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. .,Mailman School of Public Health, Columbia University, New York, USA.
| | - M Altfeld
- Ragon Institute of MGH, MIT and Harvard University, Boston, USA. .,Leibniz Institute for Experimental Virology, Heinrich Pette Institute, Hamburg, Germany.
| | - C M Gray
- National Institute of Communicable Diseases, Sandringham, South Africa. .,University of Cape Town, Cape Town, South Africa.
| | - T Ndung'u
- HIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, South Africa. .,Ragon Institute of MGH, MIT and Harvard University, Boston, USA. .,KwaZulu-Natal Research Institute for Tuberculosis and HIV, University of KwaZulu-Natal, Durban, South Africa. .,Max Planck Institute for Infection Biology, Chariteplatz, D-10117, Berlin, Germany.
| |
Collapse
|